Flg Inhibitors
Items 11 to 20 of 23 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ZM 323881 hydrochloride | 324077-30-7 | sc-296861 sc-296861A | 1 mg 10 mg | $105.00 $164.00 | 1 | |
ZM 323881 hydrochloride is a potent acid halide known for its exceptional reactivity and specificity in chemical transformations. Its electrophilic character facilitates rapid acylation reactions, making it a key player in forming diverse carbonyl compounds. The compound's unique steric hindrance and electronic distribution allow for tailored interactions with nucleophiles, promoting selective pathways in synthetic chemistry. Additionally, its stability in reaction intermediates contributes to efficient product formation. | ||||||
EGF/FGF/PDGF receptor tyrosine kinase inhibitor Inhibitor | 1135256-66-4 | sc-221579 | 2 mg | $290.00 | 1 | |
EGF/FGF/PDGF receptor tyrosine kinase inhibitor exhibits remarkable selectivity in targeting specific receptor tyrosine kinases, influencing critical signaling pathways. Its unique binding affinity is attributed to precise molecular interactions that stabilize the enzyme-substrate complex. The compound's kinetic profile reveals a rapid onset of action, while its structural features enable effective modulation of downstream cellular responses. This specificity enhances its role in regulating cellular processes. | ||||||
Dovitinib, Free Base | 405169-16-6 | sc-396771 sc-396771A | 10 mg 25 mg | $170.00 $350.00 | ||
Dovitinib inhibits FGFR1 kinase activity by competitively binding to its ATP-binding pocket. This inhibits downstream signaling pathways and thereby reduces cellular proliferation and induces apoptosis in FGFR1-dependent cells. | ||||||
4,4′-Bis(4-aminophenoxy)biphenyl | 13080-85-8 | sc-267771 | 5 g | $100.00 | ||
4,4'-Bis(4-aminophenoxy)biphenyl demonstrates intriguing properties as a Flg, characterized by its ability to form robust hydrogen bonds and π-π stacking interactions. These molecular features facilitate unique conformational dynamics, influencing its reactivity and stability. The compound exhibits a distinctive electronic structure that enhances its interaction with various substrates, leading to altered reaction kinetics. Its solubility profile further supports diverse applications in material science and polymer chemistry. | ||||||
FGF Receptor Tyrosine Kinase Inhibitor IV, NP603 | sc-221613 | 5 mg | $220.00 | |||
FGF Receptor Tyrosine Kinase Inhibitor IV, NP603, exhibits remarkable selectivity in targeting fibroblast growth factor receptors, showcasing a unique binding affinity that disrupts key signaling pathways. Its structural conformation allows for effective steric hindrance, influencing downstream cellular responses. The compound's hydrophobic regions enhance its interaction with lipid membranes, while its dynamic molecular flexibility contributes to its overall stability and reactivity in complex biological environments. | ||||||
Debio-1347 | 1265229-25-1 | sc-507386 | 10 mg | $324.00 | ||
Debio 1347 inhibits FGFR1 by binding to its ATP-binding site, preventing autophosphorylation and subsequent activation of downstream pathways like MAPK and PI3K/AKT, thus inhibiting cell proliferation. | ||||||
PD 161570 | 192705-80-9 | sc-361284 sc-361284A | 5 mg 25 mg | $112.00 $446.00 | 1 | |
PD 161570 functions as a potent Flg, characterized by its ability to selectively inhibit specific protein interactions. Its unique molecular architecture facilitates strong hydrogen bonding and hydrophobic interactions, enhancing its affinity for target sites. The compound's reactivity is influenced by its electrophilic nature, allowing it to engage in rapid acylation reactions. Additionally, its conformational adaptability plays a crucial role in modulating enzyme activity and influencing cellular signaling cascades. | ||||||
Brivanib | 649735-46-6 | sc-364447 sc-364447A | 5 mg 10 mg | $263.00 $370.00 | ||
Brivanib acts as a selective Flg, distinguished by its intricate molecular design that promotes unique ligand-receptor interactions. Its structure enables effective π-π stacking and dipole-dipole interactions, enhancing binding specificity. The compound exhibits notable kinetic properties, with a propensity for rapid reversible binding, which allows for dynamic modulation of target pathways. Furthermore, its solubility characteristics facilitate efficient diffusion across biological membranes, impacting its overall reactivity profile. | ||||||
PDGFR Tyrosine Kinase Inhibitor VI, SU6668 | 210644-62-5 | sc-204175 | 5 mg | $79.00 | 9 | |
PDGFR Tyrosine Kinase Inhibitor VI, SU6668, functions as a Flg, characterized by its ability to disrupt specific signaling cascades through targeted inhibition. The compound showcases unique conformational flexibility, allowing it to adapt to various receptor sites. Its interactions are marked by hydrogen bonding and hydrophobic effects, which contribute to its selectivity. Additionally, the compound's stability in solution enhances its reactivity, facilitating interactions with downstream signaling molecules. | ||||||
PDGFR/VEGFR2 Tyrosine Kinase Inhibitor, 5-Br SU6668 | sc-222143 | 5 mg | $326.00 | |||
5-Br SU6668, a PDGFR/VEGFR2 Tyrosine Kinase Inhibitor, exhibits remarkable specificity in modulating angiogenic pathways. Its unique structural features enable it to engage in precise molecular docking, influencing receptor conformation. The compound's kinetic profile reveals a rapid association with target kinases, while its hydrophilic and lipophilic balance enhances membrane permeability. This dynamic behavior allows for effective competition with natural substrates, shaping cellular responses. | ||||||